



Endotyping Cellular and Humoral Immunoreactivity against Tartrazine in Allergic Patients: A Retrospective Study

Celso Eduardo Olivier ^{a*}, Daiana Guedes Pinto ^a,
Ana Paula Monezzi Teixeira ^a,
Cibele Silva Miguel ^a,
Raquel Acácia Pereira Gonçalves Santos ^a,
Jhéssica Letícia Santos Santana ^b
and Regiane Patussi Santos Lima ^c

^a Instituto Alergoimuno de Americana, Brazil.

^b Instituto de Ensino e Pesquisa do Hospital de Amor de Barretos, Brazil.

^c Lavoisier Laboratórios, São Paulo, Brazil.

Authors' contributions

This work was carried out in collaboration among all authors. Author CEO conceptualized the study, did data curation, formal analysis, literature review and wrote the original draft. Authors DGP, APMT, CSM, JLSS and RPSL performed laboratory procedures. Author RAPGS performed cutaneous tests. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/aji/2024/v7i1146>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/126461>

Original Research Article

Received: 22/10/2024

Accepted: 06/11/2024

Published: 11/11/2024

*Corresponding author: E-mail: celso@alergoimuno.med.br;

Cite as: Olivier, Celso Eduardo, Daiana Guedes Pinto, Ana Paula Monezzi Teixeira, Cibele Silva Miguel, Raquel Acácia Pereira Gonçalves Santos, Jhéssica Letícia Santos Santana, and Regiane Patussi Santos Lima. 2024. "Endotyping Cellular and Humoral Immunoreactivity Against Tartrazine in Allergic Patients: A Retrospective Study". *Asian Journal of Immunology* 7 (1):217-27. <https://journalaji.com/index.php/AJI/article/view/146>.

ABSTRACT

Background: Several publications report that tartrazine is responsible for IgE-mediated and non-IgE-mediated hypersensitivity reactions. There is no standardized lab exam to endotype non-IgE-mediated immunoreactivity against tartrazine besides *in vivo* provocation tests.

Aim: To evaluate the potential of the Tube Titration of Precipitins (TTP) and the Leukocyte Adherence Inhibition Test (LAIT) to endotype humoral and cellular immunoreactivity against tartrazine in patients clinically diagnosed with non-IgE-mediated allergic phenotypes associated with various non-IgE-mediated allergic conditions.

Study Design: We retrospectively examined the medical charts of two cohorts of patients diagnosed with the aforementioned allergic phenotypes with clinical suspicion of tartrazine hypersensitivity, who were investigated with the help of TTP (first cohort) or *ex vivo* challenge tests monitored by LAIT (second cohort) against tartrazine.

Methodology: The registered results of the semi-quantitative serum TTP against 1 mg/mL tartrazine solution were distributed in ranges through a cascade distribution chart to outline the variability of the results inside the first cohort. The registered results of the Leukocyte Adherence Inhibition (LAI) percentage promoted by the *ex vivo* challenges with 1 mg/mL tartrazine solution were distributed in ranges through a cascade distribution chart to outline the variability of results inside the second cohort. The statistical characteristics of these cohorts were calculated.

Results: Most positive TTP results concentrated on the higher dilutions. The mean was estimated at 1:290; the standard deviation was estimated at 1:200. The LAI ranged from 0% to 88%. The mean was 35.4%; the standard deviation was 24,7%. The cascade distribution graph demonstrates that the LAIT distribution is mainly over the negative and weaker results.

Conclusion: Our preliminary results support that the TTP and LAIT performed with 1 mg/mL tartrazine solution may discriminate diverse humoral and cellular immunoreactivity degrees in patients suffering from several non-IgE-mediated allergic conditions, encouraging further prospective studies and validation.

Keywords: Asthma; rhinitis; endotype; hypersensitivity; leukocyte adherence inhibition test; precipitins; tartrazine; urticaria.

ABBREVIATIONS

LAI : Leukocyte Adherence Inhibition

LAIT : Leukocyte Adherence Inhibition Test

TTP : Tube Titration of Precipitins

1. INTRODUCTION

Tartrazine is a tasteless synthetic yellow-lemon water-soluble aromatic mono-azo dye used as its sodium salt, potassium salt, calcium salt, and aluminum lake [1]. Azo dyes (organic compounds bearing the functional group R-N=N-R' where R and R' are aryl groups) such as tartrazine, sunset yellow, and carmoisine are additives aggregated to provide color to medicines and processed foods in products such as canned vegetables, chewing gum, frankfurters, macaroni, soft drinks, spaghetti, bread, butter, cheese, concentrated fruit juices, ice cream, jellies, tomato ketchup, jam, candies, pickles, and others, regardless any intrinsic nutrition value, preservative activity or health benefit [2,3].

Tartrazine may be used alone or associated with aluminum lakes or blue colorants to produce

green shades [1,4]. Tartrazine is also known by the codes: E102, INS 102, CI 19140, FD&C Yellow 5, Yellow 5 Lake, Acid Yellow 23, Food Yellow 4, and trisodium 1-(4-sulfonatophenyl)-4-(4-sulfonatophenylazo)-5-pyrazolone-3-carboxylate [5].

The European Food Safety Authority Panel calculated a theoretical maximum daily exposure to tartrazine of 8.1 mg/kg/day for adults and 13.1 mg/kg/day for children, establishing an Acceptable Daily Intake (ADI) of 7.5 mg/kg/day [6]. However, these limits do not represent enough environmental safety since they can damage aquatic fauna such as the freshwater zebrafish (*Danio rerio*) [7].

Tartrazine has been known to cause allergic reactions since 1958 [8]. The extensive clinical spectrum of tartrazine hypersensitivity includes urticaria, angioedema, anaphylactic shock, asthmatic bronchitis, rhinitis, throat tickle, cough, vasculitis (purpura), and contact dermatitis [9-14]. A patient with textile contact dermatitis after using a yellow cloth was diagnosed with the help of a skin contact test with tartrazine [15].

The fact that tartrazine is a drug additive with no proper function besides coloring pills and solutions makes it one of the first aims to diagnose when facing allergic conditions elicited by colored medications such as antihistamines and steroids used to treat allergies and asthma [16].

Tartrazine belongs to a select group of aromatic substances (aspirin, salicylates, sulfites, benzoates, and azo dyes) known to produce non-IgE-mediated "allergic-like" dose-dependent symptoms such as urticaria and bronchospasm at remarkably similar molar doses in allergic patients submitted to progressive oral challenges [17-19]. These reactions appear to have a familiar incidence, presenting cross-reactivity among these substances [20].

Tartrazine hypersensitivity has been associated with aspirin sensitivity; however, the mechanism is obscure since aspirin inhibits the cyclooxygenases responsible for producing prostaglandins, while tartrazine does not have this effect [21,22]. A multicenter study performed with patients with aspirin-induced asthma found a frequency of 2.6% of patients with tartrazine hypersensitivity [23].

Due to tartrazine hypersensitivity, there is a worldwide concern to substitute tartrazine from medicines and industrialized food for natural colorants such as curcumin (E100), riboflavin (E101), beta-carotene (E160a), annatto (E160b), or other chemical dyes such as quinoline yellow (E104), or yellow iron oxide (E172) [24,25].

Azo dyes are relatively small compounds that cannot interact alone with antibodies, so in hypersensitivity reactions, they function as haptens, usually linked to complex proteins, such as albumins [26]. Commercial anti-tartrazine polyclonal antibodies are usually produced for research purposes by conjugating tartrazine with ovalbumin or allophycocyanin [27]. Although one can find commercial lab kits to detect specific IgE against conjugated tartrazine, antibodies of the IgE class are unlikely to mediate tartrazine hypersensitivity [28].

The primary laboratory marker of patients reacting to dyes is eosinophilia [29]. A radioimmunoassay inhibition assay was designed to detect anti-tartrazine IgD and IgE antibodies. However, patients diagnosed with tartrazine hypersensitivity could be distinguished from controls only by their specific IgD, not by

their specific IgE antibodies against tartrazine [30].

There is not yet any reliable routine lab exam to quantify immunoreactivity against tartrazine, and the clinical diagnosis of hypersensitivity to tartrazine is founded chiefly on *in vivo* tests based on oral or cutaneous provocations.

Cellular immunoreactivity against tartrazine (and other food additives) has already been demonstrated by *ex vivo* challenging tests monitored by the granulocytic myeloperoxidase release reaction [31]. *Ex vivo* challenges employing leukocytes to detect immunoreactivity against tartrazine were also already monitored by sulfidoleukotriene production in allergic patients [32].

The direct effect of tartrazine on lymphocytes is suggested by cytotoxic experiments employing *ex vivo* experiments employing human lymphocytes [33]. *Ex vivo* studies in cultured human leukocytes demonstrated that tartrazine at 70 µg/mL induces DNA damage, suggesting a genotoxic potential [34].

The Leukocyte Adherence Inhibition Test (LAIT) and the Tube Titration of Precipitins (TTP) are performed in our facilities as triage tests to identify immunoreactivity against suspected allergens executed before the performance of more exhaustive *in vivo* provocation tests [35-41]. The present study hypothesizes that LAIT and TTP may differentiate endotypes and degrees of immunoreactivity against tartrazine among patients suffering from common allergic phenotypes.

To evaluate the potential of the LAIT and the TTP to discriminate humoral and cellular immunoreactivity against tartrazine, we retrospectively compiled the electronic medical charts of patients clinically diagnosed with non-IgE-mediated allergic phenotypes associated with chronic and/or recurrent conditions such as rhinitis, sinusitis, conjunctivitis, bronchitis, allergic contact dermatitis, intrinsic atopic dermatitis, urticaria systemic anaphylactic reactions and/or gastrointestinal disorders who were investigated with these procedures.

2. MATERIALS AND METHODS

2.1 Subjects

After receiving Institutional Review Board approval from the Instituto Alergoimuno de

Americana (Brazil; 08/2024), we reviewed the electronic chart of 9,500 outpatients who attended our facility from January 2018 to October 2024.

The first cohort (TTP cohort) consisted of 100 outside patients clinically diagnosed with non-IgE-mediated allergic phenotypes associated with chronic and/or recurrent conditions such as rhinitis, sinusitis, conjunctivitis, bronchitis, allergic contact dermatitis, intrinsic atopic dermatitis, urticaria systemic anaphylactic reactions and/or gastrointestinal disorders. These patients had been submitted to TTP with 1 mg/mL of tartrazine solution.

The TTP cohort counted 23 males and 77 females; mean age 35,5 years; SD 21.8 years; range 1 to 79 years; median 35 years; modes = 9, 27, 42, 43, and 69 (each appeared four times); geometric mean = 25.3 years.

The second cohort (LAIT cohort) consisted of 100 outside patients clinically diagnosed with non-IgE-mediated allergic phenotypes associated with chronic and/or recurrent conditions such as rhinitis, sinusitis, conjunctivitis, bronchitis, allergic contact dermatitis, intrinsic atopic dermatitis, urticaria systemic anaphylactic reactions and/or gastrointestinal disorders. These patients had been submitted to an *ex vivo* allergen challenge test with tartrazine solution 1mg/mL monitored with LAIT.

The LAIT cohort counted 36 males and 64 females; mean age 40 years; SD 21.2 years; range 4 to 90 years; median 38 years; mode = 22 (appeared four times); geometric mean = 33.2 years.

This study did not include patients under biological and/or systemic anti-inflammatory therapy. These procedures were offered to patients with clinical suspicion of tartrazine hypersensitivity who demonstrated a non-detectable specific IgE against tartrazine and a non-reactive or inconclusive skin test done with tartrazine 1 mg/mL solution [42].

2.2 Tartrazine Solution

The tartrazine solution was prepared with powdered tartrazine diluted with distilled water at 1 mg/mL to perform the allergic skin tests, TTP, and LAIT.

2.3 *Ex vivo* Investigation: Leukocyte Adherence Inhibition Test

2.3.1 Procedure for allergen *ex vivo* challenging

We performed the LAIT as previously described [43-52]. Shortly, each donor's fresh plasma was divided into two parts and used in parallel *ex vivo* challenging tests with tartrazine acetate solution 1 mg/mL and the unchallenged plasma assay. We collected plasma with high leukocyte content (buffy coat) from the heparinized tube after one hour of sedimentation at 37°C. Then, we distributed aliquots of 100 µL into Eppendorf tubes kept under agitation for 30 minutes (200 rpm at 37°C) with tartrazine solution (10µL of a solution with 1mg/mL) or without tartrazine solution (when used as control).

2.3.2 Procedure for adherence assay

After incubation, the plasma was allocated into a standard Neubauer hemocytometer counting chamber with a plain, non-metallic glass surface and left to stand for 2 hours at 37 °C in the humidified atmosphere of the covered water bath to allow leukocytes to adhere to the glass. Next, we counted the leukocytes, removed the coverslip, and washed the chamber by immersion in a beaker with PBS (phosphate-buffered saline) at 37°C. Then, we added a drop of PBS to the hemocytometer's chamber and allocated a clean coverslip over it. The remaining cells were counted in the same squares as previously examined.

2.3.3 Procedure for calculation

The percentage of Leukocyte Adherence (LA) of each assay was estimated as: (the number of leukocytes observed on the hemocytometry chamber after washing divided by the number of leukocytes observed on the hemocytometry chamber before washing) and multiplied by 100 (%). The Leukocyte Adherence Ratio (LAR) was estimated based on the ratio between the LA from the antigen-specific challenged plasma and the LA from the unchallenged control plasma: $LAR = LA \text{ of the challenged sample} / LA \text{ of unchallenged control plasma} \times 100 \%$. To further calculate the Leukocyte Adherence Inhibition (LAI), we subtracted the LAR from 100 (%). We employed the LAI results for the cascade distribution chart and the statistics calculations, both performed with the help of the Microsoft Excel® statistical package.

2.4 *In vitro* Investigation: Tube Titration of Precipitins (TTP)

As previously reported, the semi-quantitative TTP against the tartrazine solution was performed in a transparent vitreous tube array [53-55]. Shortly, the patient's blood was collected in a clot-activator collecting tube. After separation, the serum was centrifugated at 2,000 rpm for 10 minutes. The allergen extracts were allocated in sets of eleven glass tubes at progressive duplicated serum dilutions. The progressive dilutions were combined with the 15 μ L of the antigen (1 mg/mL) with 250 μ L of the patient's serum, progressively diluted into physiological saline solution (NaCl 0,9%) in the dilution ratios of 1:1; 1:2; 1:4; 1:8; 1:16; 1:32; 1:64; 1:128; 1:256; and 1:512. One tube was a blank control done with the water and serum to observe occasional spontaneous precipitation (Sia Test). After 24 hours, the tubes were examined, and the titers (the highest dilution factor that yields a positive reading) were recorded [56].

3. RESULTS

As a retrospective survey, there was no research protocol; therefore, we report the incidental immune investigation as registered in the digital medical charts.

The cascade distribution graph showed a distribution range of TTP results. There was one negative result, while more positive results concentrated on the higher dilutions (Fig. 1). The mean was estimated at 1:290; the median was 1:256; the standard deviation was estimated at 1:200; the mode was 1:512 (appeared 42 times). All Sia tests were negative.

The LAI ranged from 0% to 88%. The mean was 35.4%; the median was 36.5%; the standard deviation was 24,7%; the mode was 0% (appeared nineteen times). The cascade distribution graph demonstrates distribution mostly over the negative and weaker results (Fig. 2). Nineteen patients (19%) ignored the allergen, presenting no inhibition of leukocyte adherence (LAI = 0%) after contact of the plasma with the tartrazine solution. Some patients showed low or moderate immunoreactivity during the *ex vivo* challenge test, while most displayed strong immunoreactivity, suggesting tartrazine's participation in the hypersensitivity condition.

4. DISCUSSION

To detect humoral and cellular immunoreactivities against tartrazine, we retrospectively compiled the data registered in an Excell® spreadsheet resulting from TTP and TIAL against tartrazine at our facilities. These triage tests are performed before the *in vivo* provocation tests when skin tests are unfeasible due to the patient's skin conditions.

The humoral and the cellular immunoreactivity profiles present divergent results. The humoral profile, represented by the TTP, presented the most results in the more diluted titrations, suggesting that most patients produced prominent levels of anti-tartrazine antibodies. However, the cellular profile, represented by the TIAL, presented most results in the negative or the weaker LAI results, suggesting a less determinant participation of the cellular immunoreactivity. The fact that the results were obtained from two cohorts and measured by different methodologies (quantitative and semi-quantitative) did not allow us to perform a paired t-test analysis.

The primary strategy of Personalized Medicine is to diagnose the endotypes responsible for the disease's phenotypes [57]. The former limited capacity to diagnose hypersensitivity had created in physicians the common idea that diagnosing a single hypersensitivity would be enough to treat their patients, conferring them a "mono-sensitization label". As medical knowledge and resources advance, more diagnoses are being performed, making physicians aware that polysensitization is more a rule than an exception. Panallergens responsible for cross-reactivity between allergens from diverse sources, such as tropomyosins or profilins, contribute to this awareness, allowing a more extensive comprehension of the allergic conditions [58,59]. Cross-reactivity among azo dyes and similar preservatives, such as the sulfides, a group of inorganic salts added to processed foods and also naturally found in *Allium* spices and fermented beverages, is a large field for studies that must be explored to understand hypersensitivity conditions better, endotyping their mechanisms, and tailor the treatment of allergic patients [60,61].

The great insight Gell and Coombs gave in the sixties resisted the test of time and now is amplified as a compass to understand the wide variety of hypersensitivity reactions that are still

far from being completely elucidated [62,63]. Endotyping underlying hypersensitivity mechanisms may help distinguish superimposable phenotypes presenting similar symptoms that may hamper establishing a precise diagnosis [64].

TTP and LAIT assays do not identify the exact immune mechanisms responsible for clinical hypersensitivity; instead, they are general immune markers of the humoral and cellular responses against allergens, quantifying an exposome measurement [65].

This retrospective proof of concept analysis demonstrated several degrees of humoral and cellular immunoreactivity, as demonstrated by TTP and LAIT against tartrazine in two cohorts of patients with several allergic conditions. None of the patients presented an exclusive reaction to tartrazine. Every patient was simultaneously evaluated for other suspected allergens, demonstrating positive and negative results. Our results suggest that tartrazine can elicit humoral and cellular immunoreactivity in allergic patients, theoretically able to impair their allergic symptoms.




Fig. 1. Cascade distribution chart of the Tube Titration of Precipitins (TTP on the x-axis) resulting from the tartrazine solution against the serum of a cohort of 100 tests/subjects (y-axis)




Fig. 2. Cascade distribution chart of the range groups of Leukocyte Adherence Inhibition (LAI) results (x-axis %) of ex vivo tartrazine solution monitored by the Leukocyte Adherence Inhibition Test (LAIT), according to the respective number of outcomes over a cohort with 100 tests/subjects (y-axis)

5. CONCLUSION

In vitro humoral assays and *ex vivo* cellular challenges can detect immunoreactivity against potentially lethal allergens without posing any risk for the patient and are occasionally employed in daily routine when conventional allergy diagnostic procedures are not elucidative or contra-indicated [66]. Our preliminary results show that the TTP and LAIT may differentiate diverse degrees of immunoreactivity against tartrazine in patients clinically diagnosed with non-IgE-mediated cutaneous allergies. This methodology can provide a socioeconomic impact since the methodologies to perform TTP and LAIT are inexpensive and can be performed in a single lab attached to the facilities with minimum laboratory equipment. However, the propaedeutic meaning of these results and the possibility of interferences must be better established [67]. More studies focused on the quality-by-design approach with prospective larger double-blind cohorts need to evaluate the potential contribution of TTP and LAIT for endotyping immunoreactivity of patients suspected of symptomatic hypersensitivity against tartrazine and other similar food processing additives [68].

6. FUTURE DIRECTIONS AND RECOMMENDATIONS FOR CLINICAL PRACTICE

The primary intended use of *in vitro* or *ex vivo* allergen challenges is to spare the patients from being submitted to exhaustive and dangerous *in vivo* challenge tests. Exploring the humoral and the cellular arms of immune systems, the TTP and TIAL alone or combined may represent, in the near future, a tool for allergists to construct an etiologic diagnosis from their patients, as well as determine the endotypes (mechanisms) of hypersensitivity, in order to choose more convenient and personalized therapies for them.

7. LIMITATIONS

This study is a proof-of-concept retrospective analysis of data collected over six years. There was no protocol research, and the subject's data was limited to the essentials available on our electronic sheets. Therefore, we could not establish a cross-comparison between positive and negative controls to validate the results. The number of subjects is appropriate for a

preliminary study; however, future studies must be more comprehensive. The lack of a research protocol implies the possibility of a bias produced by the physician's point of view who indicated the exam (CEO) based on a clinical suspicion led purely by the anamnesis, physical examination, routine lab exams, and allergic skin tests. The study lost many of these patients to follow-up, so assuring the relationship between the immunoassays' results and the patient's clinical outcome is impossible.

CONSENT AND ETHICAL APPROVALS

As a retrospective survey of results recorded *in cognito*, consent was given collectively by the institution's ethics committee following the principles of the Declaration of Helsinki [69].

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

ACKNOWLEDGEMENTS

The Instituto Alergoimuno de Americana funded this work. We want to thank the laboratory technicians Alessandra Vieira de Oliveira and Luciana Sacilotto for their help with the exams.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. König J. Food colour additives of synthetic origin. In: Scotter MJ, ed. Colour Additives for Foods and Beverages. Oxford: Woodhead Publishing; 2015:35-60.
2. Barciela P, Perez-Vazquez A, Prieto MA. Azo dyes in the food industry: Features, classification, toxicity, alternatives, and regulation. Food Chemical Toxicol. 2023;178:113935.
3. Smith LJ, Slavin RG. Drugs containing tartrazine dye. J Allergy Clinical Immunol. 1976;58(4):456-470.
4. Smith J. Food Additive User's Handbook. New York: Blackie and Son Ltd; 1991.

5. WHO. Tartrazine. Available:<https://apps.who.int/food-additives-contaminants-jecfa-database/Home/Chemical/3885> 2021. Accessed August, 2024, 2024.
6. European Food Safety Authority. Additives Nutrient Sources Added to Food Scientific Opinion on the Re-evaluation Tartrazine (E 102). *EFSA Journal*. 2009;7(11):1331.
7. Silva J, Fracacio R. Toxicological and ecotoxicological aspects of tartrazine yellow food dye: A literature review. *Revista Brasileira de Ciências Ambientais*. 2021;56(1):137–151. DOI:<https://doi.org/110.5327/Z21769478746>
8. Lockey SD. Allergic reactions due to FDC Yellow number 5, tartrazine, an aniline dye used as a coloring and identifying agent in various steroids. *Ann Allergy*. 1959;17:719-721.
9. Collins-Williams C. Clinical Spectrum of Adverse Reactions to Tartrazine. *J Asthma*. 1985;22(3):139-143.
10. Cripp LH. Allergic vascular purpura. *J Allergy Clin Immunol*. 1971;48(1):7-12.
11. Schneiweiss F. Tartrazine anaphylaxis. *Ann Allergy*. 1981;46(5):294.
12. Desmond RE, Trautlein JJ. Tartrazine (FD & C yellow #5) anaphylaxis: A case report. *Ann Allergy*. 1981;46(2):81-82.
13. Trautlein JJ, Mann WJ. Anaphylactic shock caused by yellow dye (FD & C No. 5 and FD & C No. 6) in an enema (case report). *Ann Allergy*. 1978;41(1):28-29.
14. Dipalma JR. Tartrazine sensitivity. *Amer Fam Physician*. 1990;42(5):1347-1350.
15. Roeleveld CG, Ketel WG. Positive patch test to the azo-dye tartrazine. *Contact Dermatitis*. 1976;2(3):180.
16. Simon RA. Adverse reactions to drug additives. *J Allergy Clin Immunol*. 1984; 74(4 Pt 2):623-630.
17. Corder EH, Buckley CE, III. Aspirin, salicylate, sulfite and tartrazine induced bronchoconstriction. Safe doses and case definition in epidemiological studies. *J Clin Epidemiol*. 1995;48(10):1269-1275.
18. Ros AM, Juhlin L, Michaëlsson G. A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. *Br J Dermatol*. 1976;95(1): 19-24.
19. Michaëlsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. *Br J Dermatol*. 1973;88(6):525-532.
20. Stevenson DD, Simon RA, Lumry WR, Mathison DA. Adverse reactions to tartrazine. *Journal of Allergy and Clinical Immunology*. 1986;78(1):182-191.
21. Settupane GA, Pudupakkam RK. Aspirin intolerance. III. Subtypes, familial occurrence, and cross-reactivity with tartrazine. *Journal of Allergy and Clinical Immunology*. 1975;56(3):215-221.
22. Gerber JG, Payne NA, Oelz O, Nies AS, Oates JA. Tartrazine and the prostaglandin system. *J Allergy Clin Immunol*. 1979; 63(4):289-294.
23. Virchow C, Szczeklik A, Bianco S, et al. Intolerance to Tartrazine in Aspirin-Induced Asthma: Results of a Multicenter Study. *Respiration*. 2009;53(1):20-23.
24. Expert Panel on Additives. Safety and efficacy of iron oxide black, red and yellow for all animal species. *EFSA J*. 2016; 14(6):e04482.
25. Younes M, Castle L, Engel KH, et al. Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive. *EFSA J*. 2019;17(3):e05626.
26. Masone D, Chanforan C. Study on the interaction of artificial and natural food colorants with human serum albumin: A computational point of view. *Computat Biol Chem*. 2015;56:152-158.
27. Moneret-Vautrin DA, Demange G, Selve C, Grilliat JP, Savinet H. Induction of reaginic hypersensitivity to tartrazine in the rabbit immunization by ingestion of the covalent conjugate tartrazine-human serum albumin (author's transl). *Annales d'Immunologie*. 1979;130c(3):419-430.
28. Weltman JK, Szaro RP, Settupane GA. An analysis of the role of IgE in intolerance to aspirin and tartrazine. *Allergy*. 1978;33(5): 273-281.
29. Chafee FH, Settupane GA. Asthma caused by FDC approved dyes. *J Allergy*. 1967; 40(2):65-72.
30. Weliky N, Heiner DC. Hypersensitivity to chemicals. Correlation of tartrazine hypersensitivity with characteristic serum IgD and IgE immune response patterns. *Clin Exp Allergy*. 1980;10(4):375-394.
31. Titova ND. Use of the granulocytic myeloperoxidase release reaction to diagnose food additive allergies. *Klin Lab Diagn*. 2011(3):42-44.
32. Worm M, Vieth W, Ehlers I, Sterry W, Zuberbier T. Increased leukotriene production by food additives in patients

- with atopic dermatitis and proven food intolerance. Clin Exp Allergy. 2001;31(2): 265-273.
33. Atılı Şekeroğlu Z, Güneş B, Kondaş Yedier S, Şekeroğlu V, Aydın B. Effects of tartrazine on proliferation and genetic damage in human lymphocytes. Toxicol Mecha Methods. 2017;27(5):370-375.
 34. Floriano JM, da Rosa E, do Amaral QDF, et al. Is tartrazine really safe? In silico and ex vivo toxicological studies in human leukocytes: A question of dose. Toxicol Res. 2018;7(6):1128-1134.
 35. Kuratsuji T. Studies on leukocyte adherence inhibition test. Part II. Clinical applications of LAI test to detect delayed type hypersensitivity in infants and children. Keio J Med. 1981;30(2):65-69.
 36. Olivier CE, Pinto DG, Teixeira APM, et al. Evaluating Non-IgE-mediated Allergens' immunoreactivity in patients with "Intrinsic" persistent rhinitis with help of the leukocyte adherence inhibition test. European Journal of Medical and Health Sciences. 2023;5(1):17-22.
 37. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Evaluating Non-IgE-Mediated Allergens' immunoreactivity in patients formerly classified as "Intrinsic" asthmatics with help of the leukocyte adherence inhibition test. Eur J Clin Med. 2023;4(2):1-7.
 38. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test to the diagnosis of innate Non-IgE-mediated immunoreactivity against *Alternaria alternata*. Asian J Immunol 2023;6(1):243-251.
 39. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPG, Lima RPS. Contribution of the leukocyte adherence inhibition test to the diagnosis of innate Non-IgE-mediated immunoreactivity against *saccharomyces cerevisiae*. Asian J Immunol. 2023;6(1):234-241.
 40. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test to the diagnosis of Non-IgE-mediated immunoreactivity against *candida albicans* in patients with atopic dermatitis. Asian J Immunol. 2023; 6(1):268-276.
 41. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Contribution of the leukocyte adherence inhibition test in diagnosing Non-IgE-Mediated immunoreactivity against *Aspergillus fumigatus* in patients with allergic rhinitis and asthma. Asian J Immunol. 2024;7(1):12-20.
 42. Olivier CE, Argentão DGP, Santos RAPG, Silva MD, Lima RPS, Zollner RL. Skin scrape test: an inexpensive and painless skin test for recognition of immediate hypersensitivity in children and adults. The Open Allergy Journal. 2013;6:9-17.
 43. Olivier CE, Lima RPS, Pinto DG, Santos RAPG, Silva GKM, Lorena SLS, et al. In search of a tolerance-induction strategy for cow's milk allergies: significant reduction of beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization. Clinics. 2012;67(10):1171-1179.
 44. Olivier CE, Santos RAPG, Lima RPS, Argentão DGP, Silva GKM, Silva MD. A Novel Utility for an Old Method: The Leukocyte Adherence Inhibition Test Is an Easy Way to Detect the Immunoreactive Interference of the Collection Tube Anticoagulant on Cellular Immunoassays. Journal of Cell Adhesion. 2014;Article ID 860427:1-6
Available:<http://dx.doi.org/10.1155/2014/860427>
 45. Olivier CE, Pinto DG, Lima RPS, Silva MD, Santos RAPG, Teixeira APM, et al. Assessment of Immunoreactivity against therapeutic options employing the leukocyte adherence inhibition test as a tool for precision medicine. Eur J Clin Med. 2021;2(3):40-45.
 46. Olivier CE, Pinto DG, Santos RAPG, Lima RPS. Dextran's interference over the leukocyte adherence inhibition test. Academia Letter. 2021;3792.
 47. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Immunoreactivity against *Dermatophagoides pteronyssinus* Assessed by the Leukocyte adherence inhibition test in patients with intrinsic atopic dermatitis and correlated "Intrinsic" Non-IgE-mediated allergic conditions. Eur J Clin Med. 2021;2(6):45-50.
 48. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test to the evaluation of cellular immunoreactivity against latex extracts for

- Non—IgE-Mediated latex-fruit-pollen syndrome in allergic candidates to exclusion diets and allergic desensitization. *Eur J Clin Med.* 2022;3(1):11-17.
49. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the leukocyte adherence inhibition test for the evaluation of immunoreactivity against gluten extracts in Non—IgE-mediated / non-autoimmune gluten-related disorders. *Eur J Clin Med.* 2022;3(2):1-7.
50. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Leukocyte adherence inhibition test to the assessment of immunoreactivity against cow's milk proteins in Non—IgE-Mediated gastrointestinal food allergy. *Eur J Clin Med.* 2022;3(2):38-43.
51. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPG, Lima RPS. Contribution of the leukocyte adherence inhibition test to the diagnosis of immunoreactivity against cobalt. *Asian J Immunol.* 2023;6(1):174-184.
52. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Exploring the role of leukocyte adherence inhibition test in assessing Non-IgE mediated immunoreactivity to benzoic acid in allergic patients. *Asian J Immunol.* 2024;7(1):63-70.
53. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Intrinsic atopic dermatitis: Titration of precipitins in the screening of food allergens for prescription of elimination diets and desensitization strategies. *Eur J Clin Med.* 2021;2(6):1-9.
54. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPG, Lima RPS. Endotyping cellular and humoral immunoreactivity against aluminum in allergic patients: A retrospective study. *Asian J Immunol.* 2024;7(1):149-158.
55. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Endotyping Non-IgE-Mediated immunoreactivity to *Dermatophagoides farinae*: Implications for allergic patients. *Asian J Immunol.* 2024;7(1):90-99.
56. Williams CA, Chase MW. CHAPTER 13 - Precipitation Reactions. In: *Reactions of Antibodies with Soluble Antigens.* Academic Press. 1971;3:1-102.
57. Jutel M, Gajdanowicz P. Chapter 5 - Revised Disease Nomenclature Including Disease Endotypes. In: Agache I, Hellings P, eds. *Implementing Precision Medicine in Best Practices of Chronic Airway Diseases.* Academic Press. 2019;27-29.
58. Hauser M, Roulias A, Ferreira F, Egger M. Panallergens and their impact on the allergic patient. *Allergy Asthma Clin Immunol.* 2010;6(1):1.
59. Gordon JM, DeVries ZC. Identification of the pan-allergen tropomyosin from the common bed bug (*Cimex lectularius*). *Sci Rep.* 2024;14(1):7281.
60. Kuruvilla ME, Lee FE-H, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. *Clin Rev Allergy Immunol.* 2019;56(2):219-233.
61. Olivier CE, Pinto DG, Teixeira APM, Miguel CS, Santos RAPG, Santana JLS, et al. Endotyping cellular and humoral immunoreactivity against allium spices and sulfites preservatives in allergic patients. A retrospective study. *Asian J Immunol.* 2024;7(1):185-200.
62. Gell PGH, Coombs RRA. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, eds. *Clinical Aspects of Immunology.* 2nd ed. Oxford: Blackwell Scientific Publications. 1968;575-596.
63. Jutel M, Agache I, Zemelka-Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. *Allergy.* 2023;78(11):2851-2874.
64. Olivier CE. Allergic sinusitis, allergic migraine, and sinus headaches. *Online J Otolaryngol Rhinol.* 2024;7(1):OJOR.MS.ID.000652. DOI:000610.033552/OJOR.002024.000607.000652.
65. Chung MK, House JS, Akhtari FS, et al. Decoding the exposome: Data science methodologies and implications in exposome-wide association studies (ExWASs). *Exposome.* 2024;4(1):osae001.
66. Wedi B, Kapp A. Zelluläre In-vitro-Allergiediagnostik. *Der Hautarzt.* 2010; 61(11):954-960.
67. Anouar S, Hazim R, Brahim A. Interferences in immunological assays: Causes, detection, and prevention. *Asian J Immunol.* 2024;7(1):71-78.

68. Chiarentin L, Gonçalves C, Augusto C, Miranda M, Cardoso C, Vitorino C. Drilling into "Quality by Design" approach for analytical methods. Crit Reviews Analyt Chem. 2023:1-42.
69. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/126461>